Literature DB >> 6985643

Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP).

I Löwy, C Leclerc, E Bourgeois, L Chedid.   

Abstract

A synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), was previously shown to enhance polyclonal antibody response in murine spleen cell cultures. When MDP was added to the culture together with a potent murine B cell mitogen (such as bacterial lipopolysaccharide (LPS)), it inhibited completely the LPS-induced polyclonal activation without affecting either the 3H-thymidine incorporation or the number of blast cells in cultures. Strong suppression of mitogen-induced polyclonal activation by MDP was obtained by using a large range of cell concentrations in cultures and over various dosage levels of the stimulating mitogens (LPS and NWSM). An inhibition could be obtained even when MDP was added 24 hr after the addition of the mitogen, and highly significant suppression was observed in the absence of cell division in the cultures.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6985643

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Trace levels of peptidoglycan in serum underlie the NOD-dependent cytokine response to endoplasmic reticulum stress.

Authors:  Raphael Molinaro; Tapas Mukherjee; Robert Flick; Dana J Philpott; Stephen E Girardin
Journal:  J Biol Chem       Date:  2019-04-17       Impact factor: 5.157

Review 2.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

3.  Chronic hypersensitivity pneumonitis produced in the rabbit by the adjuvant effect of inhaled muramyl dipeptide (MDP).

Authors:  H B Richerson; M T Suelzer; P A Swanson; J E Butler; W C Kopp; E F Rose
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

4.  In vitro characteristics on human lymphocyte functions of a new immunomodulatory agent, a cyclic peptide, cyclomunine.

Authors:  P Niaudet; G Beaurain; J Leibowitch; J F Bach
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.